23rd Dec 2015 14:54
LONDON (Alliance News) - Biofrontera AG on Wednesday said it has been granted a small business waiver by the US Food and Drug Administration which exempts it from the USD2.3 million application fee for its Ameluz drug.
The biopharmaceutical company had already paid the fee in June but will now receive a refund.
"This is good news for our company and its balance sheet shortly before Christmas. We are pleased that FDA has accepted our application for a waiver, and we are now able to reclaim the PDUFA fee," Chief Executive Hermann Lübbert said in a statement.
Shares in Biofrontera were untraded in London on Wednesday, last quoted at 138.75 pence.
By Karolina Kaminska; [email protected] @KarolinaAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
B8F.L